Arvind N. Dasari, MD, lead investigator of the FRESCO-2 trial, spoke about the recent approval of fruquintinib for patients with previously treated metastatic colorectal cancer.
Approval Alert | Fruquintinib for Previously Treated Metastatic Colorectal Cancer
Results from the phase 3 FRESCO-2 trial support the approval of fruquintinib for patients with previously treated metastatic colorectal cancer.
Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
FDA Approves Revumenib in R/R NPM1-Mutant AML
5
